Liu Hong-Wei, Lu Yu-Tong, Ren Yong-Bo, Meng Yan
Department of Ophthalmology, First Affiliated Hospital of Jiamusi University, Jiamusi, China.
Medicine (Baltimore). 2020 Jun 5;99(23):e20356. doi: 10.1097/MD.0000000000020356.
Bimatoprost has been reported to treat primary open-angle glaucoma (POAG) effectively. However, up-to-date, no systematic review has specifically addressed the efficacy and safety of bimatoprost for the treatment of POAG. Therefore, this study will propose to appraise the efficacy and safety of bimatoprost for the treatment of POAG.
We will perform a systematic search in MEDLINE, EMBASE, CINAHI, Cumulative Index to Nursing and Allied Health Literature, Allied and Complementary Medicine Database, Web of Science, Cochrane Library, Chinese Biomedical Literature Database, and China National Knowledge Infrastructure from inception up to the March 1, 2020. We will include randomized controlled trials (RCTs) for evaluating the efficacy and safety of bimatoprost for the treatment of POAG. Primary outcome is the mean intraocular pressure (IOP) reduction from baseline to the endpoint, and change in best corrected visual acuity. Secondary outcomes are contrast sensitivity, rate of progression of glaucoma, quality of life, and incidence of adverse events. Study quality will be examined by Cochrane Collaboration tool, and strength of evidence will be evaluated by Grading of Recommendations Assessment Development and Evaluation tool.
This proposed study will outline the current RCTs to assess the efficacy and safety of bimatoprost for the treatment of POAG.
The findings of this study will confirm whether bimatoprost is beneficial to patients with POAG.
INPLASY202040118.
已有报道称比马前列素可有效治疗原发性开角型青光眼（POAG）。然而，截至目前，尚无系统评价专门探讨比马前列素治疗POAG的疗效和安全性。因此，本研究旨在评估比马前列素治疗POAG的疗效和安全性。
我们将在MEDLINE、EMBASE、CINAHI、护理学与健康相关文献累积索引、补充与替代医学数据库、科学网、Cochrane图书馆、中国生物医学文献数据库和中国知网中进行系统检索，检索时间范围从建库至2020年3月1日。我们将纳入评估比马前列素治疗POAG疗效和安全性的随机对照试验（RCT）。主要结局是从基线到终点的平均眼压（IOP）降低情况以及最佳矫正视力的变化。次要结局包括对比敏感度、青光眼进展率、生活质量和不良事件发生率。研究质量将采用Cochrane协作工具进行评估，证据强度将采用推荐分级评估、制定与评价工具进行评价。
本拟进行的研究将概述当前评估比马前列素治疗POAG疗效和安全性的RCT。
本研究结果将证实比马前列素对POAG患者是否有益。
INPLASY202040118。
